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Mycobacterial diseasesObjective: Mycobacterial disease is still an important cause of morbidity and mortality in
the world. Personalized medicine is a rapidly advancing field of medicine. It uses all avail-
able omics in order to make accurate decisions about prevention, diagnosis, and treatment
of disease. Personalized medicine may be helpful to design more efficient strategies for
prevention of mycobacterial diseases and for offering better treatment options.
Methods: A literature search was conducted using search keywords ‘‘personalized
medicine’’, ‘‘individualized’’, ‘‘nontuberculous mycobacteria’’, ‘‘mycobacterium tuberculo-
sis’’, ‘‘tuberculosis’’, ‘‘genetic susceptibility’’, ‘‘genomics’’, ‘‘side effects’’, ‘‘treatment’’,
‘‘prevention’’ and ‘‘diagnosis’’ from studies that have been published by July 2014. PubMed,
Cinahl, Scopus, Embase and the Cochrane Library were searched.
Results: The advances in personalized medicine for diagnosis, treatment and prognosis of
mycobacterial diseases were addressed. A need assessment for individuating the mycobac-
terial diseases was performed. Finally, the proposed approach to personalized medicine in
mycobacterial diseases was discussed.
Conclusions: Moving toward personalized medicine in mycobacterial diseases has already
started, but needs further works to make it applicable for patient care. It will help us to
improve diagnostic and treatment strategies and possibly to deliver a better quality of
healthcare to patients.
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